Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anaprazole Sodium PK and Safety in Hepatic/Renal Impairment and Elderly
CTR20260009Phase 4Active
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anaprazole sodium in duodenal ulcer, gastroesophageal reflux disease (GERD), sponsored by Xuanzhu Biopharmaceutical. Started Jan 2026; status: active.
02
Drugs
anaprazole sodium
03
Conditions
duodenal ulcergastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on CTR20260009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260009.